New combo therapy aims to slow advanced pancreatic cancer

NCT ID NCT07126158

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding two drugs (defactinib and avutometinib) to targeted radiation therapy can help people with advanced pancreatic cancer live longer without their cancer growing. About 36 participants with borderline resectable or locally advanced pancreatic cancer will receive the combination. The study compares their outcomes to historical data from patients who had radiation alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
defactinib and avutometinib (drugs) plus stereotactic body radiotherapy (radiation)
What this could lead to
If it works, this could point toward a new treatment combination that slows the growth of advanced pancreatic cancer.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply widely. The drugs can cause side effects like fatigue or liver issues, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER OF THE PANCREAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.